TP53 and cancer: To further identify whether it was related to a non-apoptosis pathway, we tested the cells’ apoptosis using flow cytometry, and the results showed that only 17% of the cells were quantified at the early stage of apoptosis and treated with mPEG-PLGA/AMDPC at concentration of 50 μg/mL for 36 h, which indicates that the mechanism of anti-cancer effect of AMDPC may not primarily be through the typical apoptosis pathway, but may be through the upregulation of P21 expression without P53 participation.